Shots :
- The (AVT06-GL-C01) confirmatory trial investigated the efficacy, safety, and immunogenicity of AVT06 vs Eylea for the treatment of neovascular (wet) AMD
- The results revealed that the trial met its 1EP of baseline to wk. 8 in Best-Corrected Visual Acuity (BCVA) showing therapeutic similarity between AVT06 and Eylea
- AVT06, recombinant fusion protein, binds with VEGF to inhibit its activation, neovascularization and vascular permeability
Ref: Alvotech | Image: Alvotech | Press Release
Related News:- Glenmark Introduces Lirafit (Biosimilar, Liraglutide) for Type 2 Diabetes Mellitus in India
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
